Seizures, Cerebral Shutdown, and SUDEP

Alireza Bozorgi, MD, Samden D. Lhatoo, MD
Epilepsy Center, University Hospitals Case Medical Center, Cleveland, OH. Address correspondence to Samden D. Lhatoo, MD, Epilepsy Center, University Hospitals Case Medical Center, 11100 Euclid Avenue, Cleveland, OH 44022. E-mail: samden.lhatoo@uhhospitals.org

Several potential pathophysiologic phenomena, including “cerebral shutdown,” are postulated to be responsible for SUDEP. Since the evidence for a seizure-related mechanism is strong, a poor understanding of the physiology of human seizure termination is a major handicap. However, rather than a failure of a single homeostatic mechanism, such as postictal arousal, it may be a “perfect storm” created by the lining up of a several factors that lead to death.

There is strong evidence to suggest that sudden unexpected death in epilepsy (SUDEP) is a seizure-related phenomenon (1–5). The agonal pathophysiological processes in SUDEP are likely to begin during, or in the immediate aftermath of, a seizure. However, potential mechanisms are speculative. Epidemiological studies have consistently pointed to the generalized tonic–clonic seizure as the seizure type most commonly associated with SUDEP (6, 7), and almost all SUDEP reports of deaths during monitoring have occurred after generalized tonic–clonic seizures, (8–11) and often during sleep (3, 12). This seizure type is associated with more severe obtundation of sensorium in the postictal period and can be associated with cardiorespiratory dysfunction during this time. Several questions arise: How do seizures terminate, and how do termination mechanisms relate to postictal arousal? Is the extent of obtundation and subsequent postictal arousal different in the frequent generalized tonic–clonic seizures of patients with chronic intractable epilepsy, (8–11) and often during sleep (3, 12). These questions remain unanswered.

Seizure Termination and the Postictal State
The generalized tonic–clonic seizure is usually characterized by generalized tonic posturing, a phase of tremulousness or “vibration” followed by a generalized clonic phase and, usually, seizure termination within the first 2 minutes of the clinical onset of generalization (13). In some genetic generalized epilepsies (e.g., juvenile myoclonic epilepsy), there may be generalized myoclonic jerking before the tonic phase; in secondarily generalized seizures, there may be a pretonic phase where version or “figure 4” posturing occurs. However, given this relative stereotypy, there is considerable clinical as well as electrographic heterogeneity in the postictal period (14, 15). Some patients recover quickly, while others have varying periods of postictal stupor. Some have brief periods of focal or generalized EEG slowing, while others have prolonged postictal generalized EEG suppression (PGES) and recovery to baseline can sometimes take many hours. Whether this postictal electroclinical heterogeneity aids SUDEP risk-stratification is debated (9, 16). Undoubtedly, there are a number of potential influences, including those of medication effects, but none have been systematically studied.

Postictal Generalized EEG Suppression and “Cerebral Shutdown”
PGES occurs in between 8% of pediatric seizure patients (17) to 65% or more of adult patients with generalized motor seizures (9) and has been reported in several monitored SUDEP/near SUDEP cases (8–11, 18, 19) where some authors have used the term “cerebral shutdown” (19). Prolonged PGES may be an independent risk factor for SUDEP, but whether it is a surrogate marker or a direct index of cerebral and brainstem dysregulation is unclear. It has been shown that >50 seconds of PGES significantly increases the adjusted odds ratios for SUDEP (5.22; 95% CI, 1.26–21.58; p < 0.05) and for each 1-second increase in the duration of PGES, the odds of SUDEP increases by a factor of 1.7% (95% CI, 1.005–1.027; p < 0.005) (9). A recent study examining sympathetic and parasympathetic changes in seizure patients measured by electrodermal activity and heart rate variability (20). An increase in electrodermal activity response amplitude and a decrease in parasympathetic-modulated high-frequency power of heart rate variability were directly correlated to prolonged PGES. Therefore, PGES may serve as a marker of postictal autonomic dysregulation, although how these parameters are pathophysiologically associated is unclear. In another study of 48 patients with generalized tonic–clonic seizures, 13 patients with PGES were compared to 12 random controls and one seizure analyzed per individual (21). Patients with PGES were significantly more likely to have shallow recovery, delayed arousal, and, at least hypothetically, a predisposition to SUDEP. One study compared
secondarily generalized convulsive seizures with and without PGES, and found that oxygen desaturation duration and extent as well as peak end-tidal CO₂ elevation was more marked in patients with PGES (22).

At least one study has questioned the association between PGES and SUDEP, although it has important methodological differences (16). This study, which examined the EEG records of 17 SUDEP cases and matched controls, found no significant differences in either presence or duration of PGES between the two groups. However, it was carried out mainly in temporal lobe epilepsy patients undergoing presurgical evaluations for temporal lobectomy. SUDEP cases, therefore, are more likely to have had intractable epilepsy compared to surgically seizure-free controls whose risk of SUDEP was artificially removed but who were potentially biologically indistinct from cases. To negate these biases, a much larger number of controls with actively intractable epilepsy and a broader representation of different epilepsy syndromes are necessary.

Seizure Termination

Does postictal electroclinical heterogeneity reflect differences in seizure termination mechanisms in etiologically and syndromically diverse epilepsies? What bearing do these have on SUDEP? Clinical and EEG patterns of seizure termination suggest that different mechanisms operate in different situations, although none of these have been convincingly explained in humans. The 3–4 Hz generalized spike–wave discharges of the typical absence seizure terminate abruptly with an almost immediate clinical and electrographic return to the pre-seizure baseline. It has been hypothesized that the seizure termination mechanism here involves a switch-like desynchronization rather than exhaustion of neurotransmitter release, the latter potentially inducing longer lasting neuronal dysfunction than observed in absence seizures (23). Such neuronal dysfunction is usually evident in the postictal state of generalized convulsions in the form of PGES or high amplitude regional/generalized slowing of the EEG and the attendant clinical features of confusion, cognitive slowing, and even postictal coma. The focal status epilepticus of epilepsia partialis continua is an interesting phenomenon where there is failure of seizure termination but a concurrent containment of the ictal discharge that prevents secondary generalization. It is likely that different mechanisms account for each process (23).

In the generalized tonic–clonic seizure, the clonic phase EEG record shows generalized EEG suppression in between the epileptiform bursts that drive clonus. Seizure end then comprises an abrupt cessation of these bursts, followed by a more continuous PGES. Does this intermittent suppression toward the end of the clonic phase (Figure 1) indicate an actively accruing seizure termination process, and can the characterization of this throw light on subsequent PGES, particularly the prolongation associated with SUDEP? Asymmetric seizure endings (Figure 2) in some patients with generalized tonic clonic seizure patients suggest that there is no central switch or generalized desynchronization mechanism in at least the generalized tonic clonic seizures of focal epilepsy. At present, whether neurotransmitter-mediated seizure termination mechanisms comprise active inhibition or passive depletion is unknown; depolarization block, electrogenic pumps, ionic fluxes, and pH changes have all been implicated. GABA, adenosine, neuropeptide Y, endocannabinoids, and endogenous opioids have also been identified as candidate neurotransmitter systems in animal studies (24). In particular, adenosine, GABA, and opioids merit close study. Ultimately, are over-efficient inhibitory processes that drive seizure termination responsible for SUDEP? At the moment, this remains simplistic speculation.

Effect of Medication on Postictal Recovery

Postictal EEG changes have been reported to last a mean of 275 seconds in a cohort of patients with focal epilepsy (25). Only two patients in this cohort had generalized tonic–clonic seizures, each lasting 1990 and 2450 seconds, respectively, an observation of a phenomenon true to more recent studies (9, 16, 21). The only study that has looked at postictal EEG in relation to medication is a 2006 levetiracetam (11 patients) versus placebo (12 patients) study (26). The mean time for recovery of the postictal record to baseline was 90 and 130 seconds, respectively, in the two patient groups before randomization to either placebo or levetiracetam. Whereas the placebo group remained at 90 seconds, the recovery time decreased in the treatment group from 130 to 4 seconds—an apparently dramatic effect. In a small sample with subsequently unstudied and therefore unreplicated results, it is perhaps a stretch to extrapolate this to a protective effect against SUDEP; but there is a suggestion here that the postictal EEG deserves scrutiny.

Sleep, Arousal, and Serotonin

Is SUDEP, in some or all cases, a critical failure of arousal mechanisms, and do seizures in the sleep state particularly compromise arousal? Most SUDEP deaths appear to have occurred during sleep (3, 12), and the majority of eyewitness accounts and monitored SUDEP case reports support this observation (3, 7, 8, 10, 12, 27, 28). Conversely, nocturnal supervision has been reported to decrease SUDEP risk (7, 28, 29), although one recent report suggests that supervision and even trained intervention immediately after a seizure may not make a difference in some individuals (29). A systematic analysis of a SUDEP cohort of 154 patients found that those with sleep-related SUDEP were more likely to have a history of nocturnal seizures than were controls, and the presence of nocturnal seizures appeared to be a significant risk factor (OR 2.6, 95% CI 1.3–5.0) (27). However, SUDEP also occurs in patients awake at the outset; whether these patients are biologically distinct is unknown.

Serotonin predominantly plays a part in wakefulness and in the inhibition of REM sleep but may have other complex roles in normal sleep physiology. Serotonin is also thought to enhance respiration in response to hypercarbia, which can occur during seizures in humans. Abnormalities in the medullary serotonergic system have been well described in the sudden infant death syndrome (SIDS), a phenomenon with which it is tempting to draw parallels to SUDEP (30). Increased polymorphism frequencies have been identified in 25 genes in SIDS infants compared to controls, 3 of which are serotonin genes (31). Tissue receptor autoradiographic studies of brainstem tissue in SIDS patients have shown arcuate nucleus (30, 32) and more widespread brainstem reduction in SHT₁b binding, increased 5HT cells and reduction in 5HT transporter binding (32, 33), suggesting abnormalities in a system prominently...
FIGURE 1. Intracranial EEG of the generalized tonic–clonic seizure of a patient with MRI negative left temporal lobe epilepsy showing 1. onset of profound EEG suppression even before the end of the generalized clonic phase and 2. onset of postictal generalized EEG suppression.

FIGURE 2. Intracranial EEG recordings showing asymmetric generalized tonic–clonic seizure termination beginning in the left hemisphere (1) followed 11 seconds later by seizure end in the right hemisphere.
involved in cardiorespiratory homeostasis. Such studies have not been carried out in SUDEP brains.

Additional information on the serotonin theme comes from animal studies: mice with an audiogenic seizure disorder due to a genetic deletion of the 5HT2c receptor die in the postictal period if unresuscitated (34). DBA/2 strain mice, which suffer audiogenic seizures, have marked susceptibility to postictal respiratory arrest, which can be reduced when pretreated with selective serotonin reuptake inhibitors (SSRIs) (35). Prevention of seizure-induced sudden death in mice by semichronic administration of a selective serotonin reuptake inhibitor has been reported by the same group (36). When fluoxetine was administered, it significantly reduced incidences of respiratory arrest, appearing to support a subsequent report on SSRIs on respiration in patients with epilepsy (37).

**Conclusion**

In the end, as eloquently described in the triple-risk model of SIDS (30), it may be the sum of a number of unfortunate confluences that comprise the perfect storm that ends in SUDEP. For example, a generalized tonic–clonic seizure in a mature brain, genetically or otherwise predisposed to neurotransmitter-driven dysregulation of postictal arousal mechanisms, with cardiorespiratory homeostasis compromised by the prone position, and a subsequent agonal cycle of cerebral and cardiorespiratory dysfunction that ends in death. Without the depth and sophistication of current SIDS research, all this remains speculative.

**References**


Instructions
The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

1. **Identifying information.**
   Enter your full name. If you are NOT the main contributing author, please check the box “no” and enter the name of the main contributing author in the space that appears. Provide the requested manuscript information.

2. **The work under consideration for publication.**
   This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking “No” means that you did the work without receiving any financial support from any third party – that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check “Yes”. Then complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

3. **Relevant financial activities outside the submitted work.**
   This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. For example, if your article is about testing an epidermal growth factor receptor (EGF) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGF or lung cancer.

   Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work’s sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

   For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. **Other relationships**
   Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.
Section #1 Identifying Information

1. Today’s Date: 10/03/2013
2. First Name Samden Last Name Lhatoo Degree MD
3. Are you the Main Assigned Author? ☒ Yes ☐ No
   If no, enter your name as co-author:
4. Manuscript/Article Title: Seizures, Cerebral Shutdown, and SUDEP
5. Journal Issue you are submitting for:

Section #2 The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Complete each row by checking “No” or providing the requested information. If you have more than one relationship just add rows to this table.

<table>
<thead>
<tr>
<th>Type</th>
<th>No</th>
<th>Money Paid to You</th>
<th>Money to Your Institution*</th>
<th>Name of Entity</th>
<th>Comments**</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Grant</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Consulting fee or honorarium</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Support for travel to meetings for the study or other purposes</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Fees for participating in review activities such as data monitoring boards, statistical analysis, end point committees, and the like</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Payment for writing or reviewing the manuscript</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Provision of writing assistance, medicines, equipment, or administrative support.</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Other</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* This means money that your institution received for your efforts on this study.
** Use this section to provide any needed explanation.
Section #3  Relevant financial activities outside the submitted work.
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the “Add” box. You should report relationships that were present during the 36 months prior to submission.

Complete each row by checking “No” or providing the requested information. If you have more than one relationship just add rows to this table.

<table>
<thead>
<tr>
<th>Type of relationship (in alphabetical order)</th>
<th>No</th>
<th>Money Paid to You</th>
<th>Money to Your Institution*</th>
<th>Name of Entity</th>
<th>Comments**</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Board membership</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Consultancy</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Employment</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Expert testimony</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Grants/grants pending</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Payment for lectures including service on speakers bureaus</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Payment for manuscript preparation.</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. Patents (planned, pending or issued)</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9. Royalties</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10. Payment for development of educational presentations</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11. Stock/stock options</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12. Travel/accommodations/meeting expenses unrelated to activities listed.**</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13. Other (err on the side of full disclosure)</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* This means money that your institution received for your efforts.
** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

Section #4  Other relationships
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☒ No other relationships/conditions/circumstances that present a potential conflict of interest.
☐ Yes, the following relationships/conditions/circumstances are present:

Samden Lhatoo

Thank you for your assistance.
Epilepsy Currents Editorial Board